[go: up one dir, main page]

ATE239787T1 - Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus - Google Patents

Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus

Info

Publication number
ATE239787T1
ATE239787T1 AT94925691T AT94925691T ATE239787T1 AT E239787 T1 ATE239787 T1 AT E239787T1 AT 94925691 T AT94925691 T AT 94925691T AT 94925691 T AT94925691 T AT 94925691T AT E239787 T1 ATE239787 T1 AT E239787T1
Authority
AT
Austria
Prior art keywords
hiv
oligonucleotides
immunodeficiency virus
human immunodeficiency
propagation
Prior art date
Application number
AT94925691T
Other languages
English (en)
Inventor
Todd C Peterson
Jorge Velarde Jr
Original Assignee
Gen Probe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Probe Inc filed Critical Gen Probe Inc
Application granted granted Critical
Publication of ATE239787T1 publication Critical patent/ATE239787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94925691T 1993-07-19 1994-07-19 Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus ATE239787T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9439093A 1993-07-19 1993-07-19
PCT/US1994/008407 WO1995003407A2 (en) 1993-07-19 1994-07-19 Oligonucleotides with activity against human immunodeficiency virus

Publications (1)

Publication Number Publication Date
ATE239787T1 true ATE239787T1 (de) 2003-05-15

Family

ID=22244881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925691T ATE239787T1 (de) 1993-07-19 1994-07-19 Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus

Country Status (9)

Country Link
US (2) US5629413A (de)
EP (1) EP0714436B1 (de)
JP (1) JPH09501562A (de)
KR (1) KR960704033A (de)
AT (1) ATE239787T1 (de)
AU (1) AU688364B2 (de)
CA (1) CA2166889C (de)
DE (1) DE69432635D1 (de)
WO (1) WO1995003407A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239787T1 (de) * 1993-07-19 2003-05-15 Gen Probe Inc Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5759519A (en) * 1995-06-07 1998-06-02 Gen-Probe Incorporated Method for the intracellular delivery of biomolecules using thiocationic lipids
US5711964A (en) * 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5739271A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
US5739311A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases
US5756352A (en) * 1995-06-07 1998-05-26 Gen-Probe Incorporated Thiocationic lipid-nucleic acid conjugates
US5932450A (en) * 1995-06-07 1999-08-03 Gen-Probe Incorporated Enzymatic synthesis of oligonucleotides using digestible templates
US5652126A (en) * 1995-06-07 1997-07-29 Gen-Probe Incorporated Use of restriction endonuclease sequences for cleaving phosphorothioate oligonucleotides
US5851548A (en) * 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
US5916777A (en) * 1995-06-07 1999-06-29 Gen-Probe Incorporated Enzymatic synthesis of oligonucleotides using 3'-ribonucleotide primers
US20020022261A1 (en) * 1995-06-29 2002-02-21 Anderson Rolfe C. Miniaturized genetic analysis systems and methods
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
EP1568787B1 (de) * 1997-08-08 2014-04-30 bioMérieux BV Verfahren mit Nukleinsäuresequenzen als Primer und Sonden zur Amplifikation und Erkennung von allen HIV-1 Subtypen
JP2002526109A (ja) * 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
EP1141314A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon
WO2000046403A2 (en) * 1999-02-03 2000-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OFHEALT H AND HUMAN SERVICES Methods and reagents for molecular detection of hiv-1 groups m, n and o
DE19908766C2 (de) * 1999-02-19 2001-02-15 Ulrich Schubert Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien
US6787303B1 (en) * 1999-04-01 2004-09-07 Alton Ochsner Medical Foundation Identification of a novel retrovirus associated with primary sclerosing cholangitis and autoimmune hepatitis
US6258593B1 (en) * 1999-06-30 2001-07-10 Agilent Technologies Inc. Apparatus for conducting chemical or biochemical reactions on a solid surface within an enclosed chamber
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
ATE407138T1 (de) * 2002-02-14 2008-09-15 Hope City Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
JP2004283024A (ja) * 2003-03-19 2004-10-14 Junsei Chemical Co Ltd 新規アンチセンスオリゴヌクレオチド及び抗ｈｉｖ剤
SG178016A1 (en) * 2009-07-07 2012-04-27 Agency Science Tech & Res Human immunodeficiency virus type 1 (hiv-1) detection method and kit therefor
EP3068907A4 (de) * 2013-11-14 2017-06-14 The General Hospital Corporation Gegen hiv-reservoirs gerichtete suizidkontrastmittel für theranostische tilgung
US20240240186A1 (en) * 2020-11-04 2024-07-18 Ahmed Ibrahim Mohamed Ibrahim Comb shaped antivirals ending with or without chain terminating bases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE131052T1 (de) * 1983-01-10 1987-03-19 Gen-Probe Partners, San Diego, Calif. Verfahren zum aufspueren, identifizieren und quantifizieren von organismen und viren.
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
EP0309230B1 (de) * 1987-09-21 1995-06-21 Gen-Probe Incorporated Homogener Abschirmungstest
PT88665B (pt) * 1987-10-05 1992-12-31 Ml Tecnology Ventures Lp Metodo para a marcacao com ester de acridinio e purificacao de sondas nucleotidicas
DE3907562A1 (de) * 1989-03-09 1990-09-13 Bayer Ag Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
AU669103B2 (en) * 1990-10-26 1996-05-30 Genta Incorporated Improved process for the synthesis of oligomers
JPH09500787A (ja) * 1993-07-19 1997-01-28 ジェン−プローブ・インコーポレイテッド 蛋白生産、細胞増殖および／または感染症病原体の増殖に対するオリゴヌクレオチド阻害の促進
ATE239787T1 (de) * 1993-07-19 2003-05-15 Gen Probe Inc Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus

Also Published As

Publication number Publication date
CA2166889A1 (en) 1995-02-02
KR960704033A (ko) 1996-08-31
JPH09501562A (ja) 1997-02-18
DE69432635D1 (de) 2003-06-12
AU7551194A (en) 1995-02-20
EP0714436B1 (de) 2003-05-07
WO1995003407A2 (en) 1995-02-02
AU688364B2 (en) 1998-03-12
WO1995003407A3 (en) 1995-06-22
EP0714436A1 (de) 1996-06-05
CA2166889C (en) 2001-09-11
US5629413A (en) 1997-05-13
US5919701A (en) 1999-07-06

Similar Documents

Publication Publication Date Title
ATE239787T1 (de) Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
Presti et al. Chikungunya virus, epidemiology, clinics and phylogenesis: a review
Thomas et al. Correlates of hepatitis C virus infections among injection drug users
Herold et al. Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry
Witvrouw et al. Novel inhibitors of HIV-1 integration
CA2268709A1 (en) Hiv protease inhibitors
EP0887427A3 (de) Amplifizierung und Detektion von HIV-1 und/oder HIV-2
ES2153807T1 (es) Secuencias de acido nucleico que pueden ser utilizadas como cebadores y sondas en la amplificacion y deteccion de todos los subtipos de vih-1.
KR970704768A (ko) 사람 면역결핍증 바이러스의 증식을 억제하는 화합물 및 방법(Compounds and Methods for Inhibiting Propagation of Human Immunoefficiency Virus)
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
ATE196288T1 (de) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
Konings et al. Protease mutations in HIV-1 non-B strains infecting drug-naive villagers of Cameroon
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
KR890010562A (ko) 비루스 감염의 표지 물질로서의 활성 rn 아제 l
Thao et al. HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam
ES2093554A1 (es) Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados.
Chan HIV-1 superinfection: evidence and impact
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
Kim et al. Integrase strand transfer inhibitor resistance mutations in antiretroviral treatment-naive patients in Korea: a prospective, observational study
TR199902508T2 (xx) HIV proteaz inhibit�rleri.
Schwarcz et al. Schwarcz et al. Respond to “Should We Estimate Incidence for Undefined Populations?”
Wagstaff et al. Novel Inhibitors of Nuclear Translocation of HIV-1 Integrase
Ussery et al. Antiviral Activity of the Protease Inhibitor KNI-272 In Vivo in the HIV-Infected HuPBMC-SCID Mouse Model.
Pion et al. Truncated forms of human and simian immunodeficiency virus in infected individuals and rhesus macaques are unique or rare quasispecies
KR900002787A (ko) 인체 후천성 면역부전증후군 바이러스 감염 저해제

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties